Google Translate Disclaimer

Translation on this website is provided by Google Translate, a third-party automated translator tool. The Simcoe Muskoka District Health Unit assumes no responsibility for the accuracy of translations performed by Google Translate, or for any issues or damages resulting from its use.

print header

Epidemiology

Reporting Obligations

Carbapenemase-producing Enterobacteriaceae (CPE) Infection is designated as a disease of public health significance and is reportable under the Ontario Health Protection and Promotion Act.  Report suspect and confirmed cases within one business day to the local Health Unit.

reporting form button

Aetiologic Agent

Carbapenemase-producing Enterobacteriaceae (CPE) refers to Gram-negative bacteria belonging to the Enterobactericeae family harbouring carbapenemase-encoding genes. Carbapenemases are beta-lactamases with ability to hydrolyze penicillins, cephalosporins, and carbapenems, rendering these antibiotics ineffective. As a result, there are limited antibiotic treatment options for patients with infection due to CPE and mortality is substantially increased.

The carbapenemases that are most common in Ontario currently include; New-Delhi Metallobetalactamase (NDM), Klebsiella pneumoniae (KPC), oxacillinase (OXA-48) and Verona integron-encoded metallo-betalactamases (VIM).

Clinical Presentation

Patients with CPE colonization are asymptomatic and can only be identified by active screening; however, colonizing CPE can cause infections if they gain access to sterile body sites (e.g., lungs, bladder, bloodstream).

CPE are capable of causing difficult-to-treat infections in any part of the body, including pneumonia, bloodstream infections, intra-abdominal infections, urinary tract infections, and central venous catheter infections. Mortality in patients with CPE bacteremia may be up to 50%.

Modes of Transmission

Transmission of CPE occurs via direct or indirect contact.

CPE are isolated predominantly from patients with exposures in health care facilities and can spread from person to person on the hands of healthcare workers or via shared medical equipment, particularly when hand hygiene is missed or equipment is not properly cleaned and disinfected. Transmission has also been associated with contaminated sink drains and outbreaks have occurred where CPE was transmitted between patients undergoing duodenoscopy, even when it appears that the duodenoscope was appropriately reprocessed between patients.

  • Incubation Period

The incubation period for exposure-to-illness onset is undefined. Individuals colonized with CPE may remain asymptomatic if they are in good health and undergo required medical procedures but can still act as a reservoir for transmission to others.

Factors that impair the function of the immune system (e.g. hematologic malignancy), and interventions which permit colonizing bacteria to invade (e.g. indwelling devices) increase the probability of infection with CPE.

Period of Communicability

The period of communicability of CPE persists as long as the organism is present in the gastrointestinal tract of the patient. Several studies have evaluated duration of colonization of patient populations in different countries with varying results. Patients can be intermittently positive on repeat screening and may be colonized for months to years.

Risk Factors/Susceptibility

The primary risk factor for acquiring CPE is exposure to patients in health care facilities with prevalent CPE. Patients who have received health care outside of the country or who are known contacts of CPE should be screened. People coming from the Indian subcontinent with or without exposure to health care, are also at risk.

Diagnosis & Laboratory Testing

CPE are identified by any Ontario microbiology laboratory. A case of CPE is any patient with a positive isolate of CPE, regardless of the presence of signs and symptoms of clinical findings. See Labstract.

Treatment & Case Management

Because CPE are resistant to all penicillins, cephalosporins, and carbapenems, treatment of infections is difficult and involves the use of antibiotics with poor adverse event profiles and/or reduced efficacy (e.g., colistin, tigecycline). The isolation of CPE should be considered to be a critical laboratory result.

For case management recommendations, refer to the Provincial Infectious Diseases Advisory Committee, Annex A document “Screening, Testing and Surveillance for Antibiotic-Resistant Organisms (AROs)”. Current expert recommendations are that patients remain on contact precautions for the duration of hospitalization. Pay particular attention to sink cleaning and disinfection.

Patient Information

Additional Resources

Public Health Ontario. Annex A: Screening, Testing and Surveillance for Antibiotic-Resistant Organisms (AROs) In All Health Care Settings, February 2013.

Centers for Disease Control and Prevention. “Facility Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE)”, 2015.

Public Health Ontario. “Carbapenemase-Producing Enterobacteriaceae (CPE)”, includes CPE Frequently Asked Questions and other resources.

References

Ministry of Health, Infectious Diseases Protocol - Ontario Public Health Standards, 2022.

Did you find what you were looking for today?
What did you like about this page?
How can we improve this page?
Page
Feedback

If you have any questions or concerns that require a response, please contact Health Connection directly.

Thanks for your feedback.
Failed to submit comment. Please try submitting again or contact us at the Health Unit.
Comment already submitted ...